Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the
visual improvement of patients suffering from chronic visual loss resulting from multiple
sclerosis related optic neuritis.